HSDT - ヘリウス・メディカル・テクノロジ―ズ （Helius Medical Technologies Inc.）

NEWTOWN, Pa., May 04, 2023 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (NASDAQ: HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced that the Company will release its first quarter 2023 financial results on Thursday, May 11, 2023, after the market […]

Finding the best pharma stocks to sell can be an all-or-nothing kind of business. If you score on a company making a breakthrough in a new drug or treatment, the rewards can be extreme, but investing in pharma stocks can also mean heavy expenditures on research and testing for a drug that may not perform as well as scientists hope. Even if the drug does well, the extended regulatory process can be challenging for investors hoping for positive returns. It takes some patience and a lot of know-how to invest successfully, including knowing which are the best pharma stocks to sell and when. I used the Portfolio Grader to identify some pharma stocks to sell. If you’re holding any of these F-rated stocks, it’s time to dump them now. NVAX Novavax $9.16 SGMO Sangamo Therapeutics $1.65 ALLR Allarity Therapeutics $1.44 VYNE Vyne Therapeutics $2.72 HSDT Helius Medical Technologies $0.20 CLOV Clover Health Investments $0.83 NKTR Nektar Therapeutics $0.93 Novavax (NVAX) Source: rarrarorro / Shutterstock.com Novavax (NASDAQ: NVAX ) at one time was a fashionable bet on finding a Covid-19 vaccine, but things didn’t work out and investors wanted and now it tops the list of pharma stocks to sell.

NEWTOWN, Pa., March 23, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, announced today that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value $0.001 per share, for each outstanding share of Helius Class A common stock held of record on April 3, 2023. The outstanding shares of Series B Preferred Stock will vote together with the outstanding shares of the Company’s Class A common stock as a single class exclusively with respect to any proposal to adopt an amendment to the Company’s certificate of incorporation to reclassify the outstanding shares of the Company’s Class A common stock into a smaller number of shares of such Class A common stock at a ratio specified in or determined in accordance with the terms of any such amendment, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the foregoing matter, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law.

Helius Medical Tech (NASDAQ: HSDT ) brought in sales totaling $282 thousand during Q4 according to data provided by Benzinga Pro . However, earnings decreased 374.37%, resulting in a loss of $4.89 million. Helius Medical Tech collected $196 thousand in revenue during Q3, but reported earnings showed a $1.03 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a … Full story available on Benzinga.com

Helius Medical Technologies, Inc. (NASDAQ:NASDAQ:HSDT) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ETCompany ParticipantsMichelle Bilski - In-Site CommunicationsDane Andreeff -…

PTAP Lowers the Cost of PoNS Therapy for Qualified Americans NEWTOWN, Pa., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Helius Medical Technologies (NASDAQ: HSDT) today announced the extension of a program that puts the company’s Portable Neuromodulation Stimulator (PoNS) into the hands of qualified Americans with multiple sclerosis (MS) at a significantly reduced cost. This initiative, the Patient

Helius Medical Technologies, Inc. (NASDAQ:HSDT) with the stream of 4.27% also noticed, India View, Inc. (NASDAQ:VIEW) encountered a rapid change of -3.24% in the last hour of Tuesday’s trading session. … The post Astounding Stock: Helius Medical Technologies, Inc. (NASDAQ:HSDT 4.27%), View, Inc. (NASDAQ:VIEW -3.24%) appeared first on Stocks Equity .

The share price of Helius Medical Technologies Inc. (NASDAQ:HSDT) fell to $0.22 per share on Tuesday from $0.22. While Helius Medical Technologies Inc. has underperformed by -3.24%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, HSDT fell by -95.99%, with highs and lows ranging from $5.79 […]

According to data from Benzinga Pro, during Q3, Helius Medical Tech ''s (NASDAQ: HSDT ) reported sales totaled $196 thousand. Despite a 72.97% increase in earnings, the company posted a loss of $1.03 million. Helius Medical Tech collected $119 thousand in revenue during Q2, but reported earnings showed a $3.81 million loss. What Is ROCE? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is … Full story available on Benzinga.com

Helius Medical Technologies Inc. (NASDAQ:HSDT)’s traded shares stood at 0.56 million during the latest session, with the company’s beta value hitting 1.10. At the last check today, the stock’s price was $0.23, to imply a decrease of -7.26% or -$0.02 in intraday trading. The HSDT share’s 52-week high remains $5.96, putting it -2491.3% down since … Helius Medical Technologies Inc. (NASDAQ: HSDT) Fell -2491.3% From Highs, What Does The Future Hold? Read More »

There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well have a look on, SMA50 … The post Powerful stocks to Increase Your Investments: Helius Medical Technologies, Inc. (NASDAQ:HSDT 7.12%), Best Buy Co., Inc. (NYSE:BBY 1.61%) appeared first on Stocks Equity .

The trading price of Helius Medical Technologies Inc. (NASDAQ:HSDT) closed higher on Tuesday, August 23, closing at $0.71, 29.09% higher than its previous close. Traders who pay close attention to intraday price movement should know that it fluctuated between $0.6012 and $0.7368. In examining the 52-week price action we see that the stock hit a … Should Value Hunters Buy Helius Medical Technologies Inc. (NASDAQ: HSDT) Stock? Read More »

Gainers Windtree Therapeutics, Inc. (NASDAQ: WINT ) shares jumped 55.2% to close at $0.70 on Tuesday after the company announced it has entered into a global licensing agreement for the development and commercialization of KL4 surfactant and AEROSURF. The company may receive up to $78.9 million in milestones. Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) jumped 53% to close at $1.49. Reviva Pharmaceuticals recently posted Q2 loss of $0.29 per share. Neptune Wellness Solutions Inc. (NASDAQ: NEPT ) climbed 53% to close at $3.06. Indonesia Energy Corporation Limited (NYSE: INDO ) shares gained 49.4% to close at $11.50 after gaining over 6% on Monday. China Index Holdings Limited (NASDAQ: CIH ) jumped 42.9% to close at $1.00 after the company received a preliminary non-binding proposal letter from Fang Holdings to acquire all outstanding shares of the company at $0.84 per share. Avaya Holdings Corp. (NYSE: AVYA ) jumped 38.6% to close at $1.11 after a Form 4 filing showed activity from 10% shareholder Theodore Walker Cheng-De King including purchase of company stock and exercise of put option contracts.

Source: sfam_photo / Shutterstock.com Windtree Therapeutics (NASDAQ: WINT ) is one of the biggest stock movers on Tuesday after announcing a new global licensing agreement for AEROSURF. AEROSURF is the company’s treatment for preterm infants with respiratory distress syndrome and may have other applications. The agreement is signed is with Lee’s Pharmaceutical as well as its affiliate Zhaoke Pharmaceutical . The license agreement allows for the development and commercialization of AEROSURF for any potential indications and applications. This will have the two handling all the funding for the development and sale of the treatment. Windtree Therapeutics benefits from this thanks to milestone payments and potential royalty payments included in the license agreement. This allows it to receive up to $78.9 million in milestone payments, as well as double-digit royalty payments. Craig Fraser, president and CEO of Windtree Therapeutics, said the following in a news release. ‘The out-licensing of the KL4 platform supports our portfolio prioritization and increases non-dilutive resources to progressing istaroxime on the significant opportunity in the major markets of cardiogenic shock and heart failure where recent positive data has created what we believe could be a relatively fast and less expensive developmental pathway in cardiogenic shock.” Today’s news brings with it heavy trading of WINT stock.

The shares of neurotech company Helius Medical Technologies (HSDT) climbed ~32% on rising volumes in the pre-market trading Tuesday after Roth Capital launched its coverage on the…